These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 15565818)
1. Tumor-activated prodrugs--a new approach to cancer therapy. Denny WA Cancer Invest; 2004; 22(4):604-19. PubMed ID: 15565818 [TBL] [Abstract][Full Text] [Related]
2. Prodrug strategies in cancer therapy. Denny WA Eur J Med Chem; 2001; 36(7-8):577-95. PubMed ID: 11600229 [TBL] [Abstract][Full Text] [Related]
3. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. Denny WA; Wilson WR J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483 [TBL] [Abstract][Full Text] [Related]
4. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. Tietze LF; Schmuck K Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425 [TBL] [Abstract][Full Text] [Related]
9. The role of hypoxia-activated prodrugs in cancer therapy. Denny WA Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684 [TBL] [Abstract][Full Text] [Related]
10. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT. HariKrishna D; Rao AR; Krishna DR Drug News Perspect; 2003 Jun; 16(5):309-18. PubMed ID: 12942162 [TBL] [Abstract][Full Text] [Related]
15. Design of anticancer prodrugs for reductive activation. Chen Y; Hu L Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784 [TBL] [Abstract][Full Text] [Related]
16. Prodrug activation enzymes in cancer gene therapy. Aghi M; Hochberg F; Breakefield XO J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261 [TBL] [Abstract][Full Text] [Related]
17. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Roy P; Waxman DJ Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390 [TBL] [Abstract][Full Text] [Related]
18. Targeted prodrug approaches for hormone refractory prostate cancer. Aloysius H; Hu L Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338 [TBL] [Abstract][Full Text] [Related]
19. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Denny WA Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798 [TBL] [Abstract][Full Text] [Related]
20. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy. Jung M Mini Rev Med Chem; 2001 Nov; 1(4):399-407. PubMed ID: 12369965 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]